Development of acquired resistance to targeted cancer therapy is one of the most significant clinical challenges. Acquiring resistance under drug selection pressure is a result of evolutionary adaptation to a complex and dynamic tumor microenvironment (TME). New therapy regimens combining CDK4/6
Introduction
Precision medicine is a personalized disease treatment model that tailors the therapeutic regimens for individual patients by considering the genetic heterogeneity of disease 1, 2 . Targeted cancer therapy exemplifies the concept of precision medicine through rationally-designed targeted treatment towards a tumor-specific dysregulated genetic event 3, 4 . With superior clinical efficacy and less side effects, targeted cancer therapy has become one of the major pillars of modern cancer treatment 5, 6 . However, cancer is a consistently evolving multicellular ecosystem 7 . Despite the initial clinical response to targeted therapies, drug-resistant tumors often emerge after prolonged treatments, which imposes a significant clinical challenge 8, 9 . Significant intratumoral heterogeneity of the tumor ecosystem, at both genetic and phenotypical level, is one of the primary culprits responsible for emergence of drug resistant tumors under the selection pressure of targeted therapy 10 . Majority of the research efforts on the resistance mechanisms have focused on such intratumoral heterogeneity of tumor cells, demonstrating that emergence of the drug-resistant phenotype is a result of selecting rare tumor cells with either pre-existing mutations (de novo) or newly acquired mutations (acquired) that confer resistance to specific targeted therapies 11 . In addition to the tumor cell centric mechanisms, emerging evidence started to reveal that tumor microenvironment (TME) factors (e.g. biophysical/biochemical clues, stromal cells), collaboratively contribute to the evolving path of the tumor to seemingly inevitable resistance 12 .
Modeling the dynamic nature of evolving drug resistance while capturing a holistic view of both tumor cells and the TME is essential for a systematic interrogation of resistance mechanisms and designing novel strategies to overcome resistance [12] [13] [14] . Traditionally, exploring molecular underpinnings of drug resistance relies on either one-pathway-at-a-time approach using in vitro cell culture model or bulk DNA/RNA sequencing approaches comparing drug sensitive/responsive and resistant clinical tumor samples 15, 16 . However, the in vitro models cannot capture the interplay between evolving tumor cells and the microenvironment, and bulk sequencing has limited resolution in revealing tumor heterogeneity or identifying rare cellular events that confer phenotypical significance to drug resistance 17 . Recent advances of single-cell analyses are revolutionizing the traditional paradigm of studying drug resistance by enabling a more holistic interrogation of tumor progression in response to drug treatments at an unprecedented single cell resolution [18] [19] [20] . Single-cell sequencing approaches have effectively revealed intratumoral subclonal hierarchy at diagnosis 21 , Darwinian clonal repopulation 19, 22 , epigenetic reprogramming associated with resistant tumor cells 23 and dynamic changes of tumor-associated immune landscape 18, [24] [25] [26] [27] . These pioneering studies based on single-cell analyses start to shed light on future single-cell analysis-based clinical management strategies for patients with relapsed resistant tumors 28 . 3 Trastuzumab, widely known as Herceptin™, a humanized monoclonal antibody targeting the extracellular domain of human epidermal growth factor receptor-2 (HER2), is one of the most successful examples of targeted therapies for HER2-overexpressing breast cancer 29 . Despite its significant initial therapeutic efficacy, both de novo and acquired resistance to trastuzumab have been observed in certain patients 30, 31 . Using in vitro trastuzumab-resistant cell line model, pre-clinical studies have mechanistically defined diverse intracellular signaling events conferring resistance, including but not limited to truncation of the HER2 receptor, dysregulating of PI3K/PTEN pathway, and engaging alternative survival pathways 31 . Recently, using an inducible-HER2 transgenic mouse model, Goel et.al. revealed an enhanced cyclin D1-CDK4 dependent proliferation confers trastuzumab-resistance in vivo 32 .
Targeting cyclin D1-CDK4 acts synergistically with trastuzumab and, more intriguingly, elicits antitumor immune response 33, 34 . In light of such strong preclinical evidence and together with the recent accelerated FDA approval of CDK4/6 inhibitors for estrogen receptor (ER)-positive breast cancer patients (Palbociclib, Pfizer, FDA 2015, Ribociclib, Novartis, FDA 2017, and Abemaciclib, Lilly, FDA 2017), the new combinatorial regimen of CDK4/6 inhibitors plus trastuzumab is currently under active clinical investigation 35, 36 . Despite the clinical promise of CDK4/6 inhibitor containing regimen in treating HER2+ breast cancer, one can envision that the therapeutic resistance to anti-CDK4/6 treatment will ultimately emerge. Thus, in light with current clinical trials, we reasoned that prospectively modeling the tumor evolution in response to a trastuzumab plus CDK4/6 inhibitor regimen will provide valuable insight to the potential acquired resistance mechanisms. Preclinically, proactively exploring alternative therapeutic strategies that target emerging resistance mechanisms to prevent or inhibit resistance will have a direct translational impact on ongoing clinical trials and improve the therapeutic outcome.
In this study, we prospectively modeled in vivo acquired resistance to CDK4/6 inhibitor plus trastuzumab regimen using a transgenic mouse model in parallel with the current clinical trial scenario.
We found that acquired resistance to the anti-Her2/Neu antibody plus Palbociclib combination (Ab+Pal) treatment emerged quickly after initial response. Through high-throughput single-cell RNA-seq and mass cytometry by time of flight (CyTOF) analyses of the evolving tumors over the course of treatment, including treatment naive, treatment responsive/residual disease and rapidly relapsed tumors, we revealed a distinct immunosuppressive immature myeloid cell (IMC) population infiltrated in the resistant TME.
Next, guided by single-cell analyses, we evaluated the in vivo efficacy of using combinatorial immunotherapy by concomitantly targeting IMCs and enhancing T-cell activity. Further, our rationally designed sequential combinatorial regimens enabled a durable response and sustained control of the emergence of acquired resistance in rapidly evolving HER2-positive breast cancers.
Results

Rapid emergence of resistant tumors in vivo to anti-Her2/neu and CDK4/6 combinatorial targeted therapy with an increased antigen presentation and interferon signaling.
To address the question whether long term Her2/neu and CDK4/6 inhibition in advanced HER2positive breast cancer has a sustainable therapeutic effect, we employed the MMTV-neu202 Mul transgenic mouse bearing late-stage mammary tumor (volume > 500mm 3 ) and examined their response to a continuous anti-Her2/neu antibody (Ab) plus CDK4/6 inhibitor Palbociclib (Pal) treatment. Two weeks of Ab+Pal treatment produced pronounced effects, leading to tumor regression with an average volume reduction of 52.74% (Fig. 1A ) and significant suppression of tumor cell proliferation (Supplemental Fig. 1A) . In contrast, control mice exhibited an average of 108.4% increase in tumor size over the same period, and Pal or Ab single treatment only showed a mild to moderate therapeutic effect To explore the molecular underpinnings of the development of resistant to Ab+Pal treatment, we performed single-cell RNA sequencing (scRNA-seq) on enriched tumor cells from control (naive to treatment), treatment responsive (residual disease, 10-14 days with Ab+Pal treatment, APP) and treatment resistant tumors (progressive disease, 45-75 days with Ab+Pal treatment, APR) ( Fig. 1C ). First, we used nonlinear dimensionality reduction (t-distributed stochastic neighbor embedding, t-SNE) analysis to examine global transcriptional features across tumor cells derived from control, single treatment or Ab+Pal combination treatments ( Fig. 1D ). We observed distinct distribution patterns of tumor cells among the indicated different treatment tumors, with a total of 6 clusters (Supplemental Fig. 2, A and B ).
Generally, individual cells derived from different treatments tended to cluster together as distinct clusters (cluster 1, 2, 3, 5, 6), suggesting the transcriptional profiles were greatly influenced by treatments ( Fig.   1D and Supplemental Fig. 2 , A to C). Cluster 3, 2, 5 and 1 were largely representing cells derived from control, Ab only, Pal only and APR tumors, respectively ( Fig. 1 , D and E). One exception to the seemingly mutually exclusive clustering based on treatment was cluster 4, which was characterized by the high expression of proliferation genes such as Top2a, Cdk1, Mki67 and Cenpa (Supplemental Fig. 2D ).
Cells in the cluster 4 were derived from either control, Ab or Pal single treated and combination treated resistant tumors, suggesting that subpopulation of tumor cells conferred tolerance to treatment or adapted 5 to drug selection. Cluster 6 mostly represented the cells from the responsive tumors (residual disease) ( Fig. 1 , D and E) with high expression of Ltf, Scd1, Lipa, Lrg1 and Ifrd1 genes (Supplemental Fig. 2D ).
Of particular interest is cluster 1, which is predominantly composed of cells from APR tumors ( Fig. 1E Fig. 2D ). Besides the dominant clustering as cluster 1, APR tumor cells also spread into other clusters, indicating the nature of heterogeneity.
To examine the functional implications of gene signatures unique to each cluster, we performed single-sample gene set enrichment analysis (ssGSEA) focusing on scRNA-seq data derived from control, combination treatment responsive and resistant tumors. We applied canonical pathways from KEGG, REACTOME and BIOCARTA gene sets of the C2 collection of Molecular Signatures Database (MSigDB) to each single cell to obtain enrichment score for each signature, and did pair-wise comparison by t-test ( Fig. 1F and Supplemental Fig. 2E ). Targeting G1-to-S-phase cell-cycle transition of tumor cells is recognized to be the primary mechanism of action of CDK4/6 inhibitors. Gene sets enrichment analysis revealed that, overall, G-S-phase cell-cycle transition and mitotic activity were downregulated in shortterm combination treatment responsive (residual) tumors (APP) compared to control treated tumors, while resistant tumors (APR) showed a reprogramed cell-cycle machinery with slight enhanced mitotic activity (Supplemental Fig. 2F ), which was consistent with Ki67 staining result (Supplemental Fig. 1 , A and E).
In the responsive residual tumors (APP), an enrichment of genes involved in both death receptor 'P75 NTR signaling' and 'NFκB is activated and signals survival' (Supplemental Fig. 2 , E and G), suggesting that Ab+Pal treatment induced death signaling and reprogrammed survival signaling to adapt to the treatment. In the resistant tumors (APR), notably, enrichment analysis showed that 'antigen processing and presentation' and 'interferon signaling signatures' were among the most strikingly differential To connect the canonical cell surface markers with the observed transcriptome heterogeneity of TILs, we profiled the TILs of control, APP and APR tumors using CyTOF. CD45 + live cells were analyzed using viSNE algorithm (Supplemental Fig. 5, A and B) , a data visualization tool that creates a twodimensional view of high-parameter biological information while conserving the richness of the data at the single-cell level 39 . We first observed an increase of CD11b high myeloid cells while a decrease of CD11b low cells in APR tumors compared to those of the control and APP tumors (Supplemental Fig. 5C ).
Consistent with the trend of scRNA-seq profiling and classification, responsive tumors exhibited more T and NK cells among the infiltrated CD45 + cells (Supplemental Fig. 5C ). Lymphocyte antigen 6 complex (Ly6C/G) and chemokine (C-X3-C motif) receptor 1 (Cx3cr1) are valuable markers with both phenotypic and functional significance for myeloid cells. Closer examination of CD11b high myeloid cells showed an increase of CD11b high Ly6C/G high (19.23% in APR tumors compared to 3.91% and 6.41% in control and responsive tumors, respectively) and CD11b high Ly6C/G low Cx3cr1 low (21.63% in resistant tumors compared to 9.94% and 7.41% in control and responsive tumors, respectively) subpopulations in resistant tumors ( Fig. 2D and Supplemental Fig. 5D ). Of note, CD11b and Ly6C/G (Gr-1) are recognized as phenotypic markers of mouse myeloid-derived suppressor cells (MDSCs). Immunofluorescence staining confirmed a significant decrease of CD8 + T-cell infiltration ( Fig. 2E ) and a great increase of MDSCs (Supplemental Fig. 5F ) in the resistant tumors compared to responsive tumors. Collectively, these observations revealed that APP tumors were infiltrated with more T and NK cells while, in contrast, APR TME were dominated by IMCs.
The dominant presence of IMCs suggested an immunosuppressive microenvironment in the resistant tumors. To understand the possible mechanisms involved in the transition of the immune microenvironment, the effect of Ab+Pal treatment on expression of cytokines and chemokines was investigated, as tumor-produced factors are critical for the recruitment and functional properties of TILs 14 . Single cell transcriptional analysis of tumor cells revealed that several secreted factors involved in recruitment or chemotaxis of myeloid cells were increased, including Cxcl1, Cxcl2, Tgfβ3 and lactotransferrin (Ltf) after short-term Ab+Pal treatment ( Fig. 2F ). As an immunoregulatory factor, Ltf has been reported as a driver for accumulation and acquisition of immunosuppressive activity of MDSCs 40 .
On the other hand, expression of multiple cytokines and chemokines associated with myeloid cell 8 recruitment and differentiation, including Csf1, Tgfβ2, Serpine2, Cyr61 and Lgals3 were upregulated in Ab+Pal resistant tumor cells ( Fig. 2F ). It has been shown that colony stimulating factor 1 (CSF-1) is important for development and activation of MDSCs 37, 38 . These data indicate that tumor cells are capable of evolution/adaptation through the production of multiple immunomodulatory factors to establish an immunosuppressive environment to acquire and sustain resistance to Ab+Pal combination treatment.
Single-cell transcriptome profiling annotated immature myeloid cells shared molecular characteristics of myeloid-derived suppressor cells
Noticeable in APR tumors, the infiltrating immature myeloid cells (IMCs) characterized by scRNAseq (clusters 4 and 5) possessed certain molecular characteristics of MDSCs. This observation led us to explore the potential association between the transcriptome profiling identified IMCs and the surface markers defined MDSCs through transcriptomic analysis. We employed a tumor transplantation model by transplanting APR tumors to mammary fat pads of recipient syngeneic MMTV-Neu mice (12 to14-week old). After forming palpable tumors, the recipient mice were treated with Ab+Pal for 1-3 weeks to establish/ensure the resistance phenotype. First, we isolated tumor infiltrated Gr-1+ cells (including Gr1 high Ly6G + and Gr1 dim Ly6Gpopulations) and found that these cells inhibited the proliferation of CD4+ and CD8+ T cells in vitro (Supplemental Fig. 6A ), an important functional characteristic of MDSCs 37 .
Next, Gr-1+ cells and CD45+ TILs were isolated in parallel from the transplanted Ab+Pal resistant tumors and scRNA-seq was performed ( Fig. 2G ). 2,471 cells in total (with 1,318 Gr-1+ cells and 1,153 CD45+ TILs) were analyzed after quality control filtering. Unsupervised clustering separated these heterogeneous cells into two apparent subgroups: one group was predominantly from CD45+ TILs (group I) while the other group of cells (group II) were dominated by Gr1 high Ly6G + and Gr1 dim Ly6Gcells (Supplemental Fig. 6B ). Group I cells showed high expression of macrophage genes (CD14, Emr1 or F4/80, Apoe, Lyz2) and T/NK cell-related genes (Cd3e, Nkg7, Cd4 and Cd8a), while group II cells exhibited enriched expression of MDSC related genes, Arg1 and Xbp1 (Supplemental Fig. 6C ). Thus, these two groups of cells were annotated as non-IMCs and MDSC/IMCs, respectively ( Fig. 2H ). Based on marker genes of group II cells, we generated Gr-1+ MDSCs signature (Supplementary Table 1 ). We found that Lcn2 and Mgst1, two of the marker genes of Gr-1+ MDSCs identified by scRNA-seq analysis, were also specifically present in previously identified IMCs related cells ( Fig. 2I ). Indeed, flow sorting and qPCR of APR tumors showed significant higher expression levels of both Lcn2 and Mgst1 in Gr1 + cells compared to T cells and macrophages (Supplemental Fig. 6D ). Further, single-cell gene set enrichment analysis using our custom experimentally generated Gr-1 + MDSCs signature revealed that the geneset was also enriched in the annotated IMCs, particularly in cluster 5 cells ( Fig. 2J ). This analysis demonstrated that transcriptomic profiling identified IMCs (predominately presented in the APR tumors) 9 displayed similar transcriptome profiles to previously defined Gr-1+ MDSCs. Defined by cell surface marker expressions, the MDSCs have been sub-grouped as Gr1 high Ly6G + and Gr1 dim Ly6G -MDSC, which largely reflect granulocytic/polymorphonuclear and monocytic lineage of MDSCs 37, 38 . Interestingly, based on the single cell transcriptome profiles, in our case, the Gr1 high Ly6G + and Gr1 dim Ly6Gcells were clustered closely or mixed together (Supplemental Fig. 6B ), suggesting the transcriptional similarity between these two groups, despite the distinct cell surface marker differences.
Depletion of IMCs sensitizes Ab+Pal resistant tumors to ICB treatment
We next assessed whether the increased Gr-1+ MDSCs population was functionally important for Ab+Pal resistant phenotype. After confirming the resistance phenotype of transplanted APR tumors ( 
Identification and selection of cabozantinib as a potential IMCs targeting drug
Motivated by the above results, we sought to modulate or target IMCs in APR tumor to overcome Ab+Pal resistance. With a goal of potentially repurposing existing drugs to combat the resistance, we screened the drug target portfolios of FDA-approved small molecular protein kinase inhibitors (PKIs) against the single-cell transcriptome of TILs. We observed that in addition to EGFR and/or HER2 inhibitors, cabozantinib target genes (including Met, Kit, Axl, Kdr/Vegfr2, Flt3) and Lenvatinib target genes (including Vegfr1/2/3, Pdgfr, Fgfr, Kit, Ret) were significantly enriched in TILs from APR tumors compared with those of responsive and control tumors (Supplemental Fig. 7 , A and B). Cabozantinib (Cabo), an orally bioavailable tyrosine kinase inhibitor, is approved for metastatic medullary thyroid cancer and renal cell carcinoma. Cabo also showed promising clinical activity for metastatic breast cancer in a phase 2 trial 41 and is being further investigated (ClinicalTrials.gov NCT01441947 and NCT02260531). This prompted us to conduct an in-depth examination of Cabo. Unlike TILs ( Moreover, the IMC population derived from APR tumors were largely composed of Kit and/or Met expressing IMCs (Fig. 3C ). Consistently, Gr1+ MDSC/IMCs isolated from APR tumors also showed much higher percentage of Kit and/or Met expressing cells than other non-IMCs (including macrophages, Fig. 7 , E and F). Indeed, qPCR confirmed higher expression levels of Kit and Met in CD45 + TILs from APR tumors compared to those of from either Ctrl or APP tumors (Supplemental Fig. 7G ). In addition, Gr1+ MDSC/IMC population showed the highest expression of Kit and Met among the sorted cell types (Supplemental Fig. 7H ). Altogether, our single-cell transcriptome profiling analysis and qPCR validation suggested that IMCs in APR tumors might be targetable by Cabo.
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Evaluation of single-cell RNA-seq analysis-driven therapeutic strategy for Ab+Pal resistance
To evaluate the effectiveness of Cabo, a potential MDSC/IMCs targeting inhibitor, for treating APR tumors, we again employed the transplantation model similar to previous experiments ( Fig. 2K ) to establish a cohort of mice with relatively uniform tumors. The transplanted APR tumor bearing mice were either continuously treated with Ab+Pal or with Ab+Cabo. Although Cabo monotherapy at the given dose had no anti-tumor activity, Ab+Cabo treatment significantly inhibited tumor growth ( Fig. 3D ).
Interestingly, Ab+Cabo treated tumors showed increased T cell infiltration compared to tumors with continuous Ab+Pal treatment ( Fig. 3E ) and T cell depletion during Ab+Cabo treatment resulted in significant reduction of tumor suppression ( Fig. 3F ), suggesting that the optimal therapeutic activity of Fig. 3I ). Together, these data indicated that Ab+Cabo combination, identified by single-cell transcriptome analysis, was effective in overcoming Ab+Pal resistance, and the application of immunotherapy using ICB further enhanced the anti-tumor activity.
Cabo and ICB combination subverted immunosuppressive tumor microenvironment and enhanced anti-tumor immune response
It has been previously shown that cabozantinib could synergize with immune checkpoint blockade by attenuating MDSC frequency and immunosuppressive activity in a mouse model of metastatic castration-resistant prostate cancer 42 . Since Cabo alone did not effectively suppressed the APR tumor growth ( Fig. 3D ), we speculated that the anti-tumor effect of Cabo-containing combinatorial regimen might be due in part to its activity on modulating IMC in the TME. Thus, the impact of Cabo-containing combination on the immune microenvironment was examined. First, we performed CyTOF analysis focusing on CD45 + TILs from APR transplants with either continuous Ab+Pal treatment, Ab+Cabo or Ab+Cabo+ICB combination. Both CD11b high Ly6C/G high and CD11b high Ly6C/G low Cx3cr1 low populations, which were enriched most significantly in the APR tumors as shown in Fig 
Sequential combinatorial immunotherapy enabled sustained response and significantly prolonged survival of rapidly evolving HER2/neu-positive breast cancers
Our results have shown that Ab+Pal combination treatment initially inhibited spontaneous late-stage HER2/neu-positive mammary tumor. However, resistance to Ab+Pal combination emerged in a short period ( Fig. 1B) . We found increased immunogenicity (with enhanced antigen presentation and interferon signaling) in tumor cells along with distinct immunosuppressive immature myeloid cells infiltrated in the Ab+Pal resistant TME (Fig. 2 ). Ab+Pal resistance could be effectively overcome by switching to Cabocontaining combinatorial immunotherapy, which reduced immature myeloid cells and enhanced antitumor immunity. These results prompted us to hypothesize that sequential administration of Ab+Cabo (AbC) or Ab+Cabo+ICB (AbC+ICB) combination after a short period of Ab+Pal (AbP) treatment (antitumor immunity priming) before the emergence of resistance might achieve a better therapeutic efficacy and prolonged control of tumor progression. To this end, for the control arms, MMTV-neu mice bearing spontaneous advanced tumor (size > 500mm 3 ) were continuously treated with either AbP, AbC or AbC+ICB for four weeks (Fig. 5A ). And in the sequential treatment group, the MMTV-neu tumorbearing mice were first treated with AbP for one week for priming of anti-tumor immunity, then switched to AbC or AbC+ICB treatment for another three weeks ( Fig. 5A ). We observed that sequential regimen with AbC increased progression free survival (PFS) (median of 43 days, P=0.0038) compared with AbP continuously treated mice (median of 29 days). Continuous triple combination regimen (AbC+ICB) without the priming stage exhibited comparable PFS (median of 44 days) to that of sequential AbP+AbC treatment. Notably, prior treatment of AbP priming followed by a sequential combinatorial immunotherapy regimen (AbP/AbC+ICB) further increased PFS (median of 53 days, P=0.0016 vs sequential AbP/AbC, P= 0.025 vs AbC+ICB) significantly ( Fig. 5B ). This result suggests that AbP priming is important to recondition the tumor immune microenvironment which makes the tumor more sensitive to AbC+ICB combinatorial immune therapy.
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Clinically undetectable residual tumors might gradually rebound upon discontinuation of the treatment, which imposes a significant clinical challenge. Encouraged by the significant therapeutic efficacy of AbP/AbC+ICB sequential regimen in inhibiting extremely aggressive APR tumors, we next sought to model the clinical scenario of residual disease and test whether the rebounded-tumors will acquire resistance to the sequential combinatorial immunotherapy (Fig. 5C ). Strikingly, a second round of sequential combinatorial immunotherapy was almost as effective as the first round of AbP/AbC+ICB in shrinking the rebounded-tumors ( Fig. 5D ). Throughout two courses of treatment, sequential combinatorial treatment (AbP/AbC+ICB) was well tolerated and there was no significant weight loss observed ( Fig. 5E ).
To further explore the sustainability of the sequential combinatorial regimen in controlling the tumor relapse, we transplanted the residual tumors after the second-round of sequential treatment to a cohort of recipient syngeneic MMTV-Neu mice. Compared to controls, sequential combinatorial treatment (AbP/AbC+ICB) continuously to inhibit tumor progression during the 3rd round of treatment ( Fig. 5F ), enabling a sustained control of the extremely aggressive tumors.
Discussion
Small molecule CDK4/6 inhibitors are one of the most exciting classes of targeted therapies in treating ER-positive breast cancers 43, 44 . Besides, recent studies have demonstrated an interplay between HER2 signaling and cell cycle machinery. Targeting cyclin D1-CDK4/6 complex sensitizes HER2+ tumors to anti-HER2 treatment through cyclin D1 and mTOR pathway cross-talk 45, 46 . These exciting preclinical data warranted clinical proposition of CDK4/6 inhibitors to patients with HER2+ breast cancer.
Multiple new clinical trials are currently being conducted to examine the clinical efficacy of CDK4/6 inhibitors in advanced HER2+ breast cancer patients 35, 36 . For example, the MonarcHER study (ClinicalTrials.gov identifier: NCT02675231) aims to evaluate efficacy of abemaciclib in treating patients with locally advanced or metastatic HER2+ breast cancer after prior exposure anti-HER2 therapies.
Another global phase III PATINA study (ClinicalTrials.gov identifier: NCT02947685) examines the benefits of adding palbociclib in enhancing therapeutic efficacy of current anti-HER2 therapy. Results from the PATRICIA trial (ClinicalTrials.gov Identifier: NCT02448420), a phase II study of palbociclib and trastuzumab with or without anti-ER treatment in HER2+ metastatic breast cancers, suggested that luminal subtype breast cancer correlates with a better progression-free survival compared to non-luminal tumors 47 . In line with prior pre-clinical studies and recent clinical observations, in our work, we observed similar synergistic benefit of combining CDK4/6 inhibitor palbociclib with anti-HER2 therapy in the classic MMTV-neu mouse model (Fig. 1A) . Unfortunately, despite the initial response to palbociclib plus anti-HER2 antibody (Ab+Pal group), the residual tumor under this combinatorial treatment quickly developed resistance and regained the uncontrollable tumor growth ( Fig. 1B) . While acquisition of resistance to new targeted therapy regimen is not completely unexpected, in light of current clinical trial efforts in using CDK4/6 inhibitors, this rapid development of resistance to palbociclib plus anti-HER2 therapy is concerning. An understanding of the potential mechanisms of drug resistance/inefficacy and the exploration of alternative therapeutic strategies is urgent and critical.
To dissect the cellular and molecular underpinnings of such a fast-evolving drug resistance phenotype, in the present study, we employed single-cell RNA-seq approach to characterize tumors at different stages -from naive untreated stage (Ctrl) to initial response/residual disease stage (APP) and resistant stage (APR). Although one of the most significant transcriptome changes in the APR tumor cells is the up-regulation of IFN signaling and antigen presentation, implying tumor immunogenicity elicited by Ab+Pal treatment (Fig. 1F and G), adding immune checkpoint blockade (ICB) had only a limited effect in inhibiting APR tumors ( Fig. 1H ). Interestingly, we found that the APR phenotype associated with a significant accumulation of immunosuppressive immature myeloid cell in the TME (Fig.   2 ), which could be effectively targeted by cabozantinib as identified by single-cell RNA-seq profiling ( Fig. 3 ). We observed that combinatorial immunotherapy by targeting immature myeloid cells and enhancing T-cell activity concomitantly could cooperate to exert optimal therapeutic efficacy in the treatment of aggressive resistant tumors ( Fig. 3 and Fig.4 ). Furthermore, we demonstrated that sequential combinatorial immunotherapy enabled a sustained response and significantly improved outcomes of rapidly evolving HER2/neu-positive breast cancer ( Fig. 5 ).
At the transcriptomal level, the immature myeloid cells identified in our study greatly resemble myeloid-derived suppressor cells (MDSCs). MDSCs represent a heterogeneous population of largely immature myeloid cells with an immune suppressive activity. Two major subsets (monocytic and polymorphonuclear MDSC) have been identified and characterized 37, 38 . However, the current characterization of MDSC relies mostly on the functional level (e.g. ex vivo T-cell suppression assays).
The specific and reliable molecular features contributing to the function of MDSCs, especially under the drug resistance context, have not been well defined at the single cell level. Defining the mechanistic underpinnings that drive MDSC phenotypes and their immune suppressive properties in tumors is essential for the development of MDSC-specific therapeutic interventions. In this study, we performed single cell transcriptomic analysis of Gr1 high Ly6G + and Gr1 dim Ly6Gcells derived from the APR tumors.
Interestingly, the Gr1 high Ly6G + and Gr1 dim Ly6Gcells, which are believed to represent granulocytic/polymorphonuclear and monocytic lineage of MDSCs, to a great extent, displayed 15 transcriptomic similarity under the APR context. These similarity may reflect common features of these heterogeneous and plastic myeloid cell subsets in the APR tumor context in suppressing anti-tumor immunity [48] [49] [50] . Furthermore, guided by the single-cell transcriptome signatures, targeting immature myeloid cells by switching to cabozantinib, a clinically actionable strategy, suppressed APR tumors and sensitized tumor to ICB (Fig. 3 and Fig. 5 ). Since there are a number of on-going clinical studies evaluating HER2 and CDK4/6 co-targeting in breast cancer patients, our study might be valuable in guiding future clinical practice to overcome potential emerging therapeutic resistance. Given the abundance of immature myeloid cells in APR tumors and their apparent tumor-promoting functions, targeting or modulating those cells, which have a relatively stable genome compared to cancer cells, is a clinically appealing strategy. We envision that the signature of MDSCs generated from our study may shed more light on the molecular underpinning of immature myeloid cells and guide the development of therapeutic interventions to precisely target MDSCs.
In this study, we demonstrated that identifying TME changes occurring after treatment is essential for designing more effective combinatorial regimen to combat the tumor evolution. We believe targeting these TME changes early in the disease progression/development of resistance, rather than after outright resistance, will deliver better clinical outcomes, since even short-term drug treatment induces phenotypes promoting drug resistance. Traditionally, targeted therapy is not effective once the tumor develops new mutation or engages alternative pathways to circumvent the drug target on tumor cells. In contrast to the above notion, one of the promises of immunotherapy with ICB is to deliver durable responses in disparate tumor types by reinvigorating antitumor immunity. Our results showed that long-term anti-HER2/neu antibody and CDK4/6 inhibitor combination treatment led to significant increase of immunosuppressive immature myeloid cells in the TME, which in turn diminished the efficacy of ICB. In order to maximize the utility of ICB in treating breast cancer, especially APR resistant tumors, define immune suppressive components and rationally designed combinatorial regimen to provoke tumor immunogenicity is indispensable. In this study, we have demonstrated that sequential administration combinatorial targeted therapy with additional immunotherapy could deliver a durable therapeutic efficacy, thus leading to prolonged stable disease and less drug resistance for the rapidly evolving HER2/neu positive breast cancer. This long-lasting disease control by such treatment might also engage or enhance immune memory, considering the optimal therapeutic activity of Ab+Cabo with a dependence on T cells. These findings provide insights into how and when to optimally integrate immunotherapies against even aggressive breast cancer with extensive prior treatments.
In the present study, although cabozantinib-containing regimen inhibit immature myeloid cells in the 16 APR tumor ( Fig. 4 ), we could not exclude the possible direct effect of cabozantinib on tumor cells and other stroma compartments. Our findings provided clues as to how immature myeloid cells were dominant in the Ab+Pal resistant TME. We found that expression of several cytokines and chemokines involved in recruitment, differentiation and activation of myeloid cells ( In summary, this study supports the necessity and provides potential value to use single-cell profiling to trace, characterize, and resolve tumor and TME evolution during the course of treatment, which could have a profound impact on future clinical decisions and rationally designed treatment strategies. Our preclinical findings indicated that targeting immature myeloid cells subverts immunosuppressive TME and restores the vulnerability of highly aggressive breast cancer to checkpoint blockade immunotherapy.
Along with on-going clinical trial and patient tissue biopsy, we envision that similar prospective in vivo resistance modeling and rational regimen design informed by tumor and TME alterations, could facilitate future translational precision medicine for cancer patients.
Materials and Methods
Animal model and syngeneic tumor transplantation
FVB/N-MMTV-neu (202Mul) mice (Stock No: 002376) were purchased from Jackson Lab (Ben Harbor, ME). For tumor transplantation, treatment resistant tumors were excised from MMTV-neu mice and immediately cut into small pieces of 3-5 mm in diameter. Donor tumors were transplanted into 4 th mammary fat pad of MMTV-Neu mice (12 to14-week old). Incisions were closed with wound clips which were removed after 7-10 days. Mice were monitored daily for tumor establishment and then treatment was followed. Mouse experiments were performed in accordance with protocol approved by the University of Notre Dame IACUC committee. 
In vivo treatment
Drop-seq and sequencing analysis
Single-cell transcriptomic profiles were generated using Drop-seq protocol, as previously described 51 .
Briefly, enriched tumor cell suspensions (pooled from three or four tumors) as prepared above were https://satijalab.org/seurat/) was used to perform data normalization, dimension reduction, clustering and differential expression analysis. Cells from corresponding treatment groups were merged into a single matrix. For tumor cells (sequenced by Illumina HiSeq 2500), genes with detected expression in at least 5 cells were included and cells with either less than 600 genes and 1500 UMI or more than 4000 genes and 20000 UMI were excluded. The percentage of reads aligned to mitochondrial genes per cells was calculated and cells with greater than 15% of transcripts derived from to mitochondrial genes 53 were filtered out. This resulted in 12638 genes across 4817 cells. Potential contaminating stromal cells were further removed based on the expression of Pdgfra (marker for fibroblast),
Pecam/CD31(marker for endothelial cells), CD45 and CD11b (markers for leukocytes). We finally obtained 4711 cells for further analysis. For TILs in Fig. 2B (sequenced by Illumina HiSeq 2500), genes with detected expression in at least 2 cells were included and cells with either less than 400 genes and 1200 UMI or more than 4000 genes and 30000 UMI were excluded, and cells with greater than 10% of transcripts derived from to mitochondrial genes were removed. For Fig. 2G (sequenced by NextSeq 500), genes with detected expression in at least 2 cells were included, cells with either less than 500 genes and 1500 UMI or more than 5000 genes and 50000 UMI were excluded, and cells with mitochondrial genes greater than 10% were also removed. For Fig. 4B (sequenced by NextSeq 500), genes with detected expression in at least 10 cells were included, cells with either less than 400 genes or more than 5000 genes were excluded, and cells with mitochondrial genes greater than 10% were also removed. The filtered matrix was scaled to 10,000 molecules and log-normalized per cell to correct for the difference in sequencing depth between single cells.
Gene set enrichment analysis
Single-sample gene set enrichment analysis (ssGSEA) 54 was run using GSVA v1. 28 and run in 450μL injections on a CyTOF2 instrument. CyTOF data was analyzed and visualized using Cytobank Premium (Cytobank, Inc).
Data and code availability
The single-cell RNA-seq data set has been deposited in the GEO data repository (accession number GSE122336). The custom scripts used for the described analysis are available from the corresponding authors upon reasonable request.
Statistical analysis
Statistical tests were performed in GraphPad Prism version 7.0 or in R. Data were analyzed with twotailed unpaired Student's t tests when comparing means of two groups and one-way ANOVA when 21 comparing more than two groups. Chi-square test was used to compare the proportion of cells. Survival curves were compared with the log-rank (Mantel-Cox) test. P values < 0.05 were considered significant.
Supplementary Materials
Materials and Methods
CyTOF antibodies
The following pre-conjugated antibodies purchased from Fluidigm were used in this study: CD45-089Y 
T-cell suppression assay
MDSCs were isolated from Ab+Pal treatment resistant tumors by Ficoll separation followed by using a was used for CD8 staining. After washing, sections were stained with DAPI to visualize nuclei.
Immunofluorescence imaging was performed on a multicolour fluorescent microscope (Leica DM5500 B). Five random fields were acquired from each biological sample for quantification of positive stained cells.
Flow cytometry sorting
Cryopreserved mammary tumors were enzymatically digested followed by density centrifugation. 
Cd14 x Emr1
Cd14 Emr1 both
Apoe x Lyz2
Apoe Lyz2 both X-axis, mean difference of ssGSEA enrichment score between groups; Y-axis, -log10 (P-value by t-test).
(C) Enrichment analysis of cabozantinib target genes across tumor cells grouped and plotted by different phenotypes. Each point represents a single cell.
(D) Distribution of enrichment score for cabozantinib target genes among TIL-clusters as identified in Fig.2A . Scale bar, 20 μm.
(C) Relative volumes of Ab+Pal resistant tumors after sequential treatment with Ab+Pal+ICB and Ab+Cabo+ICB (as in Fig.3F ).
Ab+Pal resistant tumors were first treated with Ab+Pal+ICB for 1 week then switched to Ab+Cabo+ICB treatment for 3 weeks.
Cabo, protein kinase inhibitor cabozantinib; ICB, immune checkpoint blockades,cocktail of anti-CTLA4 and anti-PD-1 antibodies. P-value by one-way ANOVA with Tukey's test. Supplementary Table1. Gr-1+ MDSCs signature (Top 300 differentially expressed genes of MDSCs clusters by scRNA-seq as shown in Fig. 2H) 
